Innova Therapeutics Takes Bold Step Forward in Cancer Treatment with Enci Acquisition Innova Therapeutics enhances its cancer treatment portfolio through the acquisition of Enci Therapeutics, focusing on IVT-8086, a groundbreaking antibody targeting SFRP2.

Innova Therapeutics Takes Bold Step Forward in Cancer Treatment with Enci Acquisition #USA #Mt_Pleasant #Innova_Therapeutics #Enci_Therapeutics #IVT-8086

Paradigm Therapeutics Secures Additional Funding to Accelerate SD-101 Development for Epidermolysis Bullosa Treatment Paradigm Therapeutics has announced a pivotal investment from Eshelman Ventures to fast-track the global development of SD-101, a topical treatment for Epidermolysis Bullosa.

Paradigm Therapeutics Secures Additional Funding to Accelerate SD-101 Development for Epidermolysis Bullosa Treatment #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Mt_Pleasant #SD-101

Paradigm Therapeutics Secures Additional Funding to Expedite Launch of SD-101 for Epidermolysis Bullosa Treatment Paradigm Therapeutics has received an additional $12.6 million investment from Eshelman Ventures to accelerate the global development of SD-101, a topical therapy for Epidermolysis Bullosa.

Paradigm Therapeutics Secures Additional Funding to Expedite Launch of SD-101 for Epidermolysis Bullosa Treatment #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Mt_Pleasant #SD-101

Paradigm Therapeutics Secures $12.6 Million Investment to Advance SD-101 for Epidermolysis Bullosa Treatment Paradigm Therapeutics, Inc. has announced a new $12.6 million investment from Eshelman Ventures to expedite the development of SD-101, a treatment for Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.6 Million Investment to Advance SD-101 for Epidermolysis Bullosa Treatment #USA #Paradigm_Therapeutics #Eshelman_Ventures #Mt_Pleasant #SD-101

Paradigm Therapeutics Secures $12.5 Million Investment to Advance Zorblisa™ Development for Epidermolysis Bullosa Paradigm Therapeutics, Inc. achieves a significant $12.5 million investment from Eshelman Ventures, LLC, aiming to complete Zorblisa™ development to treat all subtypes of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment to Advance Zorblisa™ Development for Epidermolysis Bullosa #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million to Advance Revolutionary EB Treatment Paradigm Therapeutics, Inc. announces a $12.5 million investment from Eshelman Ventures to support the development of SD-101, a groundbreaking therapy for Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million to Advance Revolutionary EB Treatment #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million Investment for Innovative EB Treatment Development Paradigm Therapeutics has announced a $12.5 million investment from Eshelman Ventures to finalize the development of Zorblisa™, a game-changing treatment for all subtypes of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment for Innovative EB Treatment Development #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million Investment to Advance EB Treatment SD-101 (Zorblisa™) Paradigm Therapeutics has announced a $12.5 million investment from Eshelman Ventures to support the development of SD-101, aiming to treat all types of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment to Advance EB Treatment SD-101 (Zorblisa™) #USA #Paradigm_Therapeutics #Eshelman_Ventures #Zorblisa #Mt_Pleasant